Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Kitt

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of the American College of Cardiology|February 6, 1999
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-IIB E Tardiff, R M Califf, J E Tcheng, et al.
The American Journal of Cardiology|November 13, 2001
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)J E Tcheng, J D Talley, J C O'Shea, et al.
Circulation|September 7, 2000
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial InvestigatorsM T Roe, R A Harrington, D M Prosper, et al.
Journal of the American College of Cardiology|February 24, 2001
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT InvestigatorsA B Greenbaum, R A Harrington, M P Hudson, et al.
Circulation|September 7, 2000
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialA M Lincoff, R A Harrington, R M Califf, et al.
Clinical Cardiology|November 1, 1996
Refining the treatment of women with unstable angina--a randomized, double-blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable anginaP J Goldschmidt-Clermont, S P Schulman, P F Bray, et al.
Circulation|February 18, 1997
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of the American College of Cardiology|February 6, 1999
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-IIB E Tardiff, R M Califf, J E Tcheng, et al.
The American Journal of Cardiology|November 13, 2001
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)J E Tcheng, J D Talley, J C O'Shea, et al.
Circulation|September 7, 2000
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial InvestigatorsM T Roe, R A Harrington, D M Prosper, et al.
Journal of the American College of Cardiology|February 24, 2001
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT InvestigatorsA B Greenbaum, R A Harrington, M P Hudson, et al.
Circulation|September 7, 2000
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialA M Lincoff, R A Harrington, R M Califf, et al.
Clinical Cardiology|November 1, 1996
Refining the treatment of women with unstable angina--a randomized, double-blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable anginaP J Goldschmidt-Clermont, S P Schulman, P F Bray, et al.
Circulation|February 18, 1997
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.
The American Journal of Cardiology|April 24, 1999
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin TherapyJ H Alexander, R A Harrington, R H Tuttle, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 2